Mattel Inc vs GeneDx Holdings Corp — how do they compare? Mattel Inc trades at $14.35 (market cap $4.11B), while GeneDx Holdings Corp trades at $60.65 (market cap $1.80B). The key difference: Mattel Inc is far larger — about 2.3× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| MAT | WGS | |
|---|---|---|
Market Cap | $4.11B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $22.16 | $167.51 |
52-Week Low | $13.05 | $34.51 |
Enterprise Value | $5.92B | $1.80B |
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $14.165, down 0.94% today, with a bullish technical signal supported by moving averages. The stock shows attractive valuation with a P/E of 9.17 and P/S of 0.84, while recent earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Revenue remains stable around $5.4B, and the company maintains strong brand collaborations, as seen with recent Hot Wheels and Barbie partnerships.
Outlook is cautiously optimistic given undervaluation and analyst consensus, but risks include stagnant sales, debt levels, and recent negative cash flow trends. The consensus price target is $14.60, suggesting limited upside from current levels, with investor sentiment divided between value opportunity and near-term headwinds.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Trailing returns across standard periods
Latest headlines on both assets
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →